ImmunityBio
IBRX
IBRX
164 hedge funds and large institutions have $357M invested in ImmunityBio in 2024 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 49 increasing their positions, 43 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
1.15% more ownership
Funds ownership: 8.71% → 9.85% (+1.1%)
9% more call options, than puts
Call options by funds: $26.4M | Put options by funds: $24.4M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
164
Holding in Top 10
–
Calls
$26.4M
Puts
$24.4M
Top Buyers
| 1 | +$21.3M | |
| 2 | +$4.77M | |
| 3 | +$4M | |
| 4 |
Citigroup
New York
|
+$3.7M |
| 5 |
SSWM
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
|
+$3.39M |
Top Sellers
| 1 | -$2.6M | |
| 2 | -$2.33M | |
| 3 | -$1.61M | |
| 4 |
BlackRock
New York
|
-$1.52M |
| 5 |
NYLIM
New York Life Investment Management
New York
|
-$960K |